The power of science, the power of AI - Bristol Myers Squibb

Our data science and automation teams in Lawrenceville, NJ discuss machine learning to power sequential screening, analyzing a focused deck of the BMS compound library.

The power of science, the power of AI

We believe in the power of science to address the greatest healthcare challenges of our time. Today, that power is increasingly enabled and amplified by computer science and digital capabilities like artificial intelligence (AI) and machine learning.

Predictive algorithms for molecular design, biomarker discovery and digital optimization of clinical trials are just some of the ways these technologies are already being applied today across research and development. With our scientific strategies increasingly placing prediction at the heart of drug development, the potential of these approaches to advance our mission will be even greater tomorrow.

Our strong in-house capabilities in this field are augmented by strategic collaborations that align with our broader vision, increasing our ability to accelerate the discovery of new drug candidates, advance their timely development into clinical trials, and optimize their use for improved patient outcomes. This approach is delivering already, as evidenced by the recent arrival of an AI-designed drug candidate. 

Much remains to discover, but the promise is clear. Harnessing the power of prediction will drive research innovation, optimize clinical trials and enable transformative therapeutic approaches. AI-enabled predictive technologies bring greater precision at every step, from the inception of our programs to the launch of innovative medicines that help patients prevail over serious diseases.

More Science Stories


A legacy of pioneering advances in cardiovascular disease >
Transforming cells into cancer fighters >
Unleashing the immune system to fight cancer >
Transforming patients' lives through science

The touch that transforms

2021 Annual Report


Visit to see how we're bringing a human touch to everything we do. 

The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at